Mepolizumab Market Size Forecast: How The Industry Is Expected To Grow From 2026 To 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Mepolizumab Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The mepolizumab market size has shown robust expansion in recent years. It is anticipated to increase from $2.22 billion in 2025 to $2.38 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. The historical development can be ascribed to a rising incidence of severe asthma, greater understanding of eosinophilic disorders, progress in biologics research and development, an expansion of specialty care provisions, and improved methods for diagnosing inflammatory diseases.
The mepolizumab market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period can be attributed to factors such as a heightened emphasis on personalized medicine, an expanding pipeline for biologics, an increasing need for home-based treatment solutions, progress in targeted immunotherapies, and greater healthcare investments directed towards managing chronic diseases. Key trends identified for the forecast period encompass the wider acceptance of monoclonal antibody therapies, increased utilization of biologics for managing severe asthma, a rising preference for steroid-sparing treatment alternatives, broadening clinical applications for eosinophilic disorders, and enhanced patient adherence facilitated by targeted therapies.
Get A Free Sample Report With In-Depth Market Insights:
Mepolizumab Market Growth Factors: What’s Supporting Expansion?
The global prevalence of asthma, which is steadily rising, is projected to fuel the expansion of the mepolizumab market. Asthma is characterized as a persistent respiratory ailment where the airways, or bronchi, become inflamed, constrict, and produce excessive mucus, making respiration challenging. The increased occurrence of asthma stems from individuals encountering a combination of inherited and environmental elements that can trigger inflammation within the body’s airways, thereby heightening lung sensitivity and leading to a greater incidence of the condition. Mepolizumab provides relief for asthma by diminishing inflammation attributed to eosinophils, a specific kind of white blood cell implicated in airway swelling and asthma attacks. For illustration, data from February 2026 provided by the Australian Institute of Health and Welfare (AIHW), an independent statutory agency based in Australia, indicates that asthma accounts for 2.5% of Australia’s total disease burden in 2024, stands as the primary cause of disease burden among children aged 1-9, generates approximately $1.3 billion in healthcare spending in 2023-24, and exhibits greater prevalence and hospitalization rates in boys compared to girls. Additionally, in February 2023, NHS England, a UK-based executive non-departmental public body, reported that roughly 5.4 million individuals are currently receiving asthma treatment, with approximately 160,000 new diagnoses recorded each year, and occupational exposure contributing to nearly 9–15% of adult-onset asthma cases. Consequently, the growing worldwide impact of asthma is propelling the growth of the mepolizumab market.
Mepolizumab Market Segment Trends And Revenue Contributors
The mepolizumab market covered in this report is segmented –
1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis, Chronic Obstructive Pulmonary Disease, Other Eosinophilic Disorders
2) By Age Group: Children 6 To 11 Years, Adolescents 12 To 17 Years, Adults 18 Years And Older
3) By Distribution Channel: Direct Sales, Retail Pharmacy, Online Pharmacy
4) By End User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Severe Asthma: Allergic Severe Asthma, Non Allergic Severe Asthma, Late Onset Severe Asthma
2) By Eosinophilic Granulomatosis With Polyangiitis: Active Eosinophilic Granulomatosis With Polyangiitis, Relapsing Eosinophilic Granulomatosis With Polyangiitis, Remission Phase Eosinophilic Granulomatosis With Polyangiitis
3) By Chronic Obstructive Pulmonary Disease: Chronic Bronchitis Dominant Chronic Obstructive Pulmonary Disease, Emphysema Dominant Chronic Obstructive Pulmonary Disease, Frequent Exacerbator Chronic Obstructive Pulmonary Disease
4) By Other Eosinophilic Disorders: Hypereosinophilic Syndrome, Eosinophilic Esophagitis, Eosinophilic Chronic Rhinosinusitis
Mepolizumab Market Industry Trends: What’s Reshaping Demand?
Leading companies active in the mepolizumab market are concentrating on developing innovative products, such as eosinophil-targeting biologics, to broaden therapeutic uses and enhance disease management outcomes. An eosinophil-targeting biologic is a monoclonal antibody therapy that works by inhibiting interleukin-5 to reduce inflammation mediated by eosinophils. For instance, in January 2026, GlaxoSmithKline PLC, a UK-based biopharmaceutical firm, announced the approval of Nucala (mepolizumab) by China’s National Medical Products Administration (NMPA). When added to standard inhaled treatments, this therapy demonstrates statistically significant reductions in moderate to severe exacerbations in patients with eosinophilic chronic obstructive pulmonary disease. Its approval introduces a targeted biologic option for a large patient population, facilitating improved clinical outcomes and lessening the burden of hospitalization.
Mepolizumab Market Top Companies Driving Competitive Growth
Major companies operating in the mepolizumab market are GlaxoSmithKline plc, Bio-Thera Solutions Ltd.
View The Full Mepolizumab Market Report:
Mepolizumab Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the mepolizumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mepolizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
